Radiofrequency ablation for hepatocellular carcinoma

E. Ramsay Camp, Nestor F. Esnaola, Steven A. Curley

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Hepatocellular carcinoma (HCC) is the most frequent primary hepatic tumor and the fifth most common cancer worldwide. The incidence continues to rise worldwide due to its association with hepatitis B and C viral infections. Cirrhosis is present concurrently with HCC in approximately 90% of the identified cases [1, 2]. Furthermore, the incidence of HCC increases with the severity of cirrhosis. Follow-up studies have identified HCC as one of the most common causes of death in the cirrhotic patient [3, 4]. The management of HCC, therefore, is based both on the stage of the malignancy and on the underlying functional status of the liver. Local tumor ablative techniques remain a reasonable treatment consideration for patients with disease confined to the liver who are not candidates for resection or transplantation.

Original languageEnglish (US)
Title of host publicationHepatocellular Carcinoma
Subtitle of host publicationTargeted Therapy and Multidisciplinary Care
PublisherSpringer New York
Number of pages13
ISBN (Print)9781603275217
StatePublished - Dec 1 2011


  • HCC treatment strategy
  • Open RFA laparoscopic RFA
  • RFA outcomes HCC
  • Radiofrequency ablation

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Radiofrequency ablation for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this